: iStockAnalyst.com Symbols Feed

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

Tue, 20 Oct 2009 02:19:35 GMT

At the beginning of the month, Celldex Therapeutics (NASDAQ: CLDX) announced the successful completion of its acquisition of CuraGen (formerly CRGN), which strengthens the balance sheet (approx. $85 million in cash / equivalents) while expanding the pipeline and increasing the expected news flow of clinical data catalysts for the combined entity[More...]

Curagen (NasdaqGM: CRGN)– Positive Results At ASCO 2009

Tue, 07 Jul 2009 13:25:00 GMT

Last month at the ASCO meeting, Curagen (NasdaqGM: CRGN) presented results for its lead drug, CR-011, in breast cancer and melanoma patients. CR011 had activity in both indications, however, most of the drug’s value should be ascribed to the breast cancer[More...]

Top Picks For ASCO 2009

Tue, 26 May 2009 11:44:28 GMT

The ASCO annual meeting, one of the most important events in the pharmaceutical industry will take place in Orlando next weekend. With over 4,000 abstracts to be presented this year, separating the wheat from the chaff is difficult, but below is an incomp[More...]

Spicing Up The Biotech Portfolio - Curagen and Curis

Tue, 24 Feb 2009 23:55:00 GMT

The past six months have not been kind to microcap biotech stocks, as it is hard to find a lot of love in today’s market for tiny, high risk, cash burning biotech companies. Honestly, who can blame investors for throwing stocks that offer a distant dream with minimal success rates and heavy spending? Surprisingly (or not), the negative sentiment also presents unprecedented opportunities in the microcap arena, as some microcaps are making tremendous progress, which is not yet reflected in their stock prices.

[More...]

Immunogen at ASCO Annual Meeting 2008

Tue, 15 Jul 2008 12:36:00 GMT

Normal 0 false false false [More...]

CuraGen Risk/Reward Balanced

Tue, 24 Jun 2008 18:04:15 GMT

The proceeds from the sale of Belinostat, for treating solid tumors and hematologic malignancies, strengthened CuraGen Corporation's (CRGN) balance sheet, but further weakened its pipeline, especially after the termination of its key clinical program Velafermin for the treatment of severe oral mucositis. We see this deal to be neutral to the company. The failure of the...[More...]

Immunogen and Seattle Genetics – On The Verge Of An Inflection Point

Sat, 24 May 2008 16:30:41 GMT

This year’s ASCO annual meeting should be a very exciting event for anyone who has been following the field of antibody-drug conjugates (ADCs). During the conference, investigators will present impressive clinical data generated by ADCs powered by[More...]

NASDAQ Technical Picture - Narrow Range Consolidation - May 23 2008 1:56AM

Fri, 23 May 2008 05:51:12 GMT

A truce after all the selling in the form of a NRIB on light volume. Trading might be light again tomorrow ahead of the long holiday weekend. Existing home sales out at 10:00 tomorrow might stir things up.[More...]

Analyst Comments: Altera, Texas Capital, CuraGen, Solar Panel Stocks

Thu, 17 Apr 2008 22:43:03 GMT

Altera (ALTR) recently reported revenues of $336 million in Q1:FY2008, exceeding our estimate of $326 million, mainly due to growth in sales of new products. Japan was the strongest market as sales grew 15% quarter-over-quarter and 19% year-over-year. EPS of $0.27 beat our estimate of $0.21 and street consensus of $0.23. Gross margin dipped to 65.1% from 65.7% generated in the year-ago quarter but improved from 64.1% in the previous quarter. ALTR generated 41% of...[More...]

Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation

Thu, 01 Oct 2009 18:46:00 GMT

Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today the successful completion of its acquisition of CuraGen Corporation (Nasdaq: CRGN) pursuant to the previously disclosed Agreement and Plan of Merger, dated as of May 28, 2009, by and among CuraGen, Celldex and Celldex's merger subsidiary, Cottrell Merger Sub, Inc. The Agreement and Plan of Merger was approved by CuraGen's stockholders and the issuance of shares of Celldex common stock was approved by Celldex's stockholders at special stockholder meetings held on September 30, 2009.
Concurrent with the closing of the merger, Celldex added one position to its Board of Directors and Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen, joined the Celldex Board of Directors.
"Celldex is focused on advancing our pipeline of targeted immunotherapeutics and we look forward to integrating CuraGen's assets to augment our Precision Targeted Immunotherapy Platform," stated Anthony Marucci, President and Chief Executive Officer of Celldex.

: iStockAnalyst.com Symbols Feed

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

Curagen (NasdaqGM: CRGN)– Positive Results At ASCO 2009

Top Picks For ASCO 2009

Spicing Up The Biotech Portfolio - Curagen and Curis

Immunogen at ASCO Annual Meeting 2008

CuraGen Risk/Reward Balanced

Immunogen and Seattle Genetics – On The Verge Of An Inflection Point

NASDAQ Technical Picture - Narrow Range Consolidation - May 23 2008 1:56AM

Analyst Comments: Altera, Texas Capital, CuraGen, Solar Panel Stocks

Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation

Celldex and CuraGen Stockholders Approve Acquisition of CuraGen Corporation

Celldex Therapeutics Announces Appointment of Larry Ellberger As Chairman of the Board

Celldex Reports Second Quarter and Six Month 2009 Financial Results

CuraGen Reports Second Quarter 2009 Financial Results

CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer

CuraGen Updates CR011-vcMMAE Data at ASCO

Celldex Therapeutics, Inc. Enhances Precision Targeted Immunotherapy Platform with the Acquisition of CuraGen Corporation

CuraGen to Present CR011-vcMMAE Data at ASCO

/C O R R E C T I O N -- CuraGen Corporation/

Form 4/A SHANNON TIMOTHY M For: Oct 01 (10K)

Form 4/A Finigan Paul M For: Oct 01 (10K)

Form 4/A Cassidy Sean A For: Oct 01 (10K)

Form 4/A CURAGEN CORP For: Oct 01 Filed by: ZENNER PATRICK J (10K)

Form 4/A PATRICELLI ROBERT E For: Oct 01 (10K)

Form 4/A Noble James For: Oct 01 (10K)

Form 4/A FORSGREN JOHN H For: Oct 01 (10K)

Form 4/A CURAGEN CORP For: Oct 01 Filed by: DEVITA VINCENT (10K)

Form 4 SHANNON TIMOTHY M For: Oct 01 (10K)

Form 4 Finigan Paul M For: Oct 01 (10K)